ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms

Cancer Science

Volumn 98, Issue 10, 2007, Pages 1638-1642

  Kong, Dexin ^a   Yamori, Takao ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE TRIPHOSPHATE; ISOENZYME; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; ZSTK 474;

ARTICLE; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANALYSIS; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE TRIPHOSPHATE; BINDING, COMPETITIVE; CHROMONES; ENZYME INHIBITORS; FLUOROIMMUNOASSAY; HUMANS; ISOENZYMES; KINETICS; MORPHOLINES; PHOSPHORYLATION; PROTEIN KINASES; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; TRIAZINES;

EID: 34548189038     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00580.x     Document Type: Article

References (34)

1. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988; 332: 644-6.
2. Franke TF, Kaplan DR, Cantley LC. PI3K: Downstream AKTion blocks apoptosis. Cell 1997; 88: 435-7.
3. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling. Biochem J 1998; 333: 471-90.
4. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
5. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem Sci 2005; 30: 194-204.
6. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
7. Levine DA, Bogomolniy F, Yee CJ et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005; 11: 2875-8.
8. Whyte DB, Holbeck SL. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 2006; 340: 469-75.
9. Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006; 125: 733-47.
10. Jackson SP, Schoenwaelder SM, Goncalves I et al. PI 3-kinase p110β: a new target for antithrombotic therapy. Nat Med 2005; 11: 507-14.
11. Hirsch E, Katanaev VL, Garlanda C et al. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science 2000; 287: 1049-53.
12. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 2000; 287: 1046-9.
13. Sasaki T, Irie-Sasaki J, Jones RG et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287: 1040-6.
14. Barber DF, Bartolome A, Hernandez C et al. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11: 933-5.
15. Camps M, Ruckle T, Ji H et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-43.
16. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement. J Immunol 2003; 170: 2647-54.
17. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
18. Hunter T. Signaling - 2000 and beyond. Cell 2000; 100: 113-27.
19. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002; 109: 275-82.
20. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-8.
21. Okada T, Sakuma L, Fukui Y, Hazeki O, Ui M. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J Biol Chem 1994; 269: 3563-7.
22. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6: 880-6.
23. Ihle NT, Williams R, Chow S et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004; 3: 763-72.
24. Ihle NT, Paine-Murrieta G, Berggren MI et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005; 4: 1349-57.
25. Fan QW, Knight ZA, Goldenberg DD et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341-9.
26. Yaguchi S, Fukui Y, Koshimizu I et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006; 98: 545-56.
27. Gray A, Olsson H, Batty IH, Priganica L, Downes C. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal Biochem 2003; 313: 234-45.
28. Jia Y, Quinn CM, Gagnon AI, Talanian R. Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal Biochem 2006; 356: 273-81.
29. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17: 596-603.
30. Abraham RT. Phosphatidylinositol 3-kinase related kinases. Curr Opin Immunol 1996; 8: 412-18.
31. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996; 15: 5256-67.
32. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
33. Sujobert P, Bardet V, Cornillet-Lefebvre P et al. Essential role for the p110 δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005; 106: 1063-6.
34. Billottet C, Grandage VL, Gale RE et al. A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006; 25: 6648-59.